Navigation Links
PTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer
Date:3/30/2011

SOUTH PLAINFIELD, N.J., March 30, 2011 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the appointment of Robert J. Spiegel M.D., FACP as Chief Medical Officer.  Dr. Spiegel served previously as Chief Medical Officer of Schering-Plough.  PTC also announced today the promotion of Jay Barth, M.D. to Vice President of Clinical Development.  

(Logo: https://photos.prnewswire.com/prnh/20010919/PTCLOGO)

Dr. Spiegel will report to Stuart W. Peltz, Ph.D., President and CEO of PTC Therapeutics.  "It is an exciting opportunity to be joining PTC at this time in the company's evolution," stated Dr. Spiegel.  "PTC has a broad development pipeline in genetic disorders, oncology, infectious diseases and multiple innovative preclinical programs that will be entering the clinic in the coming years.  Near term, ataluren offers PTC a unique opportunity with the potential to improve the lives of patients with serious, life-threatening rare disorders such as Duchenne and Becker muscular dystrophy and cystic fibrosis."

While at Schering-Plough, Dr. Spiegel was involved in the filing of over thirty New Drug Applications and interacted with regulatory authorities in the U.S. and globally on a regular basis, serving on the executive committees overseeing all research projects and drug licensing activities.  Dr. Spiegel joined Schering-Plough in 1983 as Director, Clinical Research, progressing through clinical operations as Vice President of Clinical Research, Senior Vice President of Worldwide Clinical Research and then becoming Chief Medical Officer in 1998.  He received his undergraduate degree, cum laude, from Yale University and his medical degree from the University of Pennsylvania.  Dr. Spiegel continues to serve on the Board of Directors and Scientific Advisory Committees of a number of companies and is an Advisor at Warburg Pincus.

In his new role as Vice President of Clinical Development, Dr. Jay Barth will lead all clinical development programs for ataluren, an investigational new drug for the treatment of nonsense mutation genetic disorders.  Ataluren is currently being investigated for use in Duchenne and Becker muscular dystrophy, cystic fibrosis, hemophilia and methylmalonic acidemia due to a nonsense mutation.  Dr. Barth received his undergraduate degree from Columbia University and his medical degree from the University of Pennsylvania School of Medicine.  He completed a residency in Pediatrics at the Columbia-Presbyterian Medical Center and a fellowship in Pediatric Gastroenterology, Liver disease and Nutrition at the New England Medical Center.  In his previous role at Merck, Dr. Barth served as Executive Director of Clinical Development and was responsible for global clinical development programs in respiratory, supportive oncology and gastroenterology.  

"We are excited to welcome Dr. Spiegel as a member of our senior management team.  Bob's extensive clinical development experience, especially his track record in leading discussions with regulatory authorities, will be invaluable as we move ataluren toward regulatory filings," stated Dr. Stuart Peltz, President and CEO of PTC Therapeutics.  "Jay has been a key contributor to the successful execution of our ataluren development plan since 2009 and the expansion of his role further supports advancement of our development efforts with ataluren."

About PTC Therapeutics, Inc.  

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered small-molecule drugs that target post-transcriptional control processes.  Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function.  PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders, oncology and infectious diseases.  PTC has developed proprietary technologies that it applies in its drug discovery activities and is the basis for collaborations with leading biopharmaceutical companies.  For more information, visit the company's web site at www.ptcbio.com.


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016 ... of the "Global Obstetrics Partnering 2010-2016: ... profile to their offering. --> ... the "Global Obstetrics Partnering 2010-2016: Deal ... to their offering. --> Research ...
(Date:2/4/2016)... Feb. 4, 2016  Edwards Lifesciences Corporation (NYSE: ... structural heart disease and critical care monitoring, announced today ... (ASR) agreement with Morgan Stanley & Co. LLC to ... is part of the Company,s previously authorized program to ... stock.  --> --> ...
(Date:2/4/2016)... -- Worldwide Radiology Oncology surgical robot markets are ... systems provide a way to improve traditional open ... systems pinpoint the delivery of radiation precisely, eliminating ... problem previously, limiting the quantity of radiation that ... far beyond what has been available, promising a ...
Breaking Medicine Technology:
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... Steve Helwig ... with a vital new community enrichment program, has teamed up with Citizens Opposed to ... children suffering from intimate abuse. To support all those victimized by the fear of ...
(Date:2/8/2016)... ... , ... Delta Dental of California and its affiliated companies announced today that ... who recently retired as president and CEO of Delta Dental of California and its ... Year , helped lead the effort to raise funds for studies to strengthen pancreatic ...
(Date:2/8/2016)... ... February 08, 2016 , ... Eating disorders and post-traumatic stress ... women and men with eating disorders report a history of trauma, research suggests ... of an eating disorder. , At the 2016 iaedp Symposium, the workshop, ...
(Date:2/8/2016)... ... 08, 2016 , ... GrassrootsHealth published data from its D*action ... diabetes in the GrassrootsHealth cohort with substantially higher vitamin D levels than a ... health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits of ...
(Date:2/8/2016)... Vegas, Nevada (PRWEB) , ... February 08, 2016 ... ... at RowdMap, Inc., will be speaking on how healthcare companies can use newly ... costs, manage the health of a population and intervene and capture the value ...
Breaking Medicine News(10 mins):